XSPY PHAR Share Price Nasdaq Stockholm
Equities
SE0009973563
Biotechnology & Medical Research
Sales 2024 * | 713M 67.33M 0 5.61B | Sales 2025 * | 789M 74.46M 0 6.21B | Capitalization | 2.71B 256M 0 21.35B |
---|---|---|---|---|---|
Net income 2024 * | 596M 56.25M - 4.69B | Net income 2025 * | - | EV / Sales 2024 * | 3.44 x |
Net cash position 2024 * | 262M 24.71M 0 2.06B | Net cash position 2025 * | - 0 - 0 | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
3.75
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
1.24% | Yield 2025 * |
-
| Free-Float | 59.23% |
Managers | Title | Age | Since |
---|---|---|---|
Per Andersson
CEO | Chief Executive Officer | 57 | 01/06/01 |
Director of Finance/CFO | 52 | 08/02 | |
Thomas Walz
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 01/15/01 | |
Carl-Johan Spak
BRD | Director/Board Member | 68 | 01/15/01 |
Chairman | 70 | 19/22/19 |
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |